Want to see AU:RAD full AI Analyst Report?
Top Page
Radiopharm Theranostics Limited
(Sydney:RAD)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
â–¼(-35.00% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily constrained by weak financial quality (large ongoing losses and significant cash burn despite improved revenue/gross margin) and bearish technicals (price below major moving averages with negative momentum). Valuation is also pressured by negative earnings (negative P/E), offering limited support.
Positive Factors
Revenue & Margin Inflection
A very large revenue inflection combined with a strong gross margin suggests the company has begun to commercialize offerings with favorable unit economics. Over 2-6 months this supports durability of product demand and potential for future margin expansion as fixed R&D and production costs are spread over higher sales volumes.
Negative Factors
Large Cash Burn
Sustained negative operating and free cash flow at this scale implies continued reliance on external financing or equity raises. Over 2-6 months this creates dilution and execution risks if new capital is needed, and constrains the company's ability to invest flexibly in parallel trials, supply scaling, or commercialization without eroding shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Inflection
A very large revenue inflection combined with a strong gross margin suggests the company has begun to commercialize offerings with favorable unit economics. Over 2-6 months this supports durability of product demand and potential for future margin expansion as fixed R&D and production costs are spread over higher sales volumes.
Read all positive factors
Radiopharm Theranostics Limited (RAD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$55.00M
Dividend YieldN/A
Average Volume (3M)4.84M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth116.02%
EPS Growth75.56%
CountryAU
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding3,928,710,000
10 Day Avg. Volume4,365,338
30 Day Avg. Volume4,842,346
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.02
Price to Sales (P/S)3.42
P/FCF Ratio-1.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$2.77M
Radiopharm Theranostics Limited Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops se...
How the Company Makes Money
null...
Radiopharm Theranostics Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
67
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.35M | 13.40M | 299.23K | 292.36K | 8.83K | 0.00 |
| Gross Profit | 21.33M | 9.81M | -21.31M | -3.00M | -2.97M | 0.00 |
| EBITDA | -43.11M | -31.65M | -45.38M | -37.11M | -18.04M | -484.75K |
| Net Income | -44.94M | -36.70M | -47.95M | -34.61M | -30.34M | -485.19K |
Balance Sheet | ||||||
| Total Assets | 91.17M | 86.48M | 72.04M | 74.95M | 83.38M | 33.44K |
| Cash, Cash Equivalents and Short-Term Investments | 34.52M | 29.12M | 18.58M | 11.70M | 26.98M | 27.09K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.00K |
| Total Liabilities | 41.23M | 43.61M | 44.68M | 29.37M | 20.42M | 158.14K |
| Stockholders Equity | 51.78M | 44.79M | 28.12M | 44.38M | 62.96M | -124.70K |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -36.65M | -22.98M | -24.73M | -38.25M | -32.91K |
| Operating Cash Flow | -37.10M | -36.65M | -22.98M | -23.20M | -9.91M | -32.91K |
| Investing Cash Flow | -6.54M | 1.77M | -320.00K | -1.53M | -28.37M | 0.00 |
| Financing Cash Flow | 42.26M | 45.43M | 29.88M | 9.22M | 65.11M | 60.00K |
Radiopharm Theranostics Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
33.27
Neutral
-25.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAD, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.27 is Neutral, neither overbought nor oversold. The STOCH value of -25.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RAD.
Radiopharm Theranostics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$4.83B | -442.68 | -1.72% | ― | 59.13% | -121.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$25.19M | -4.36 | 2509.60% | ― | ― | -137.97% | |
45 Neutral | AU$55.00M | -0.92 | -93.08% | ― | 116.02% | 75.56% | |
42 Neutral | AU$382.33M | -36.04 | -47.44% | ― | ― | -15.48% | |
41 Neutral | AU$41.63M | -0.38 | -134.65% | ― | ― | 62.72% | |
40 Underperform | AU$67.79M | -0.80 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.01
-45.83%
AU:IMU
Imugene
0.08
-0.19
-69.45%
AU:IMM
Immutep Ltd
0.05
-0.23
-83.57%
AU:TLX
Telix Pharmaceuticals
15.04
-3.16
-17.36%
AU:RAC
Race Oncology Ltd.
2.03
0.82
67.77%
AU:NOX
Noxopharm Ltd.
0.08
-0.03
-27.27%
Radiopharm Theranostics Limited Corporate Events
Radiopharm Theranostics Seeks ASX Quotation for Major Share Issuance
Aug 3, 2026
Radiopharm Theranostics Limited operates in the medical and biotechnology sector, focusing on radiopharmaceuticals and theranostic solutions that combine targeted diagnostics with therapeutic applications. The company is listed on the ASX under th...
Radiopharm Theranostics Advances RAD 101 Toward Phase 3 After Strong Trial Results
Jul 31, 2026
Radiopharm Theranostics reported positive results from its U.S. Phase 2b clinical trial of imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint of concordance with MRI in recurrent brain metastases. The program bene...
Radiopharm Theranostics Sets Target Market for Free Attaching Options
Jul 30, 2026
Radiopharm Theranostics Limited has issued a target market determination for free attaching options to be offered alongside new shares under a prospectus dated 30 July 2026.The attaching options are designed for investors acquiring shares in the o...
Radiopharm Theranostics Launches Multi-Part Capital Raise With Speculative Securities
Jul 30, 2026
Radiopharm Theranostics Limited has released a transaction-specific prospectus outlining a capital raising that includes a two-tranche share placement of up to 448,839,531 new shares at $0.015 to raise up to $6.7 million, alongside a Share Purchas...
Radiopharm Theranostics Shares Reinstated to Trading After Capital Raise Update
Jul 24, 2026
Radiopharm Theranostics has had its securities reinstated to quotation on the ASX, after a suspension that was in place pending a capital-raising announcement. The move indicates that the company has provided sufficient disclosure about its fundin...
Radiopharm outlines capital raising plans and risk warnings for oncology radiopharma platform
Jul 24, 2026
Radiopharm Theranostics has released a capital raising presentation outlining its strategy as a multi-asset radiopharmaceutical platform in oncology, spanning both diagnostic and therapeutic products. The materials emphasize that the presentation ...
Radiopharm Theranostics plans large share and warrant issue to bolster capital base
Jul 24, 2026
Radiopharm Theranostics Limited has lodged an Appendix 3B with the ASX outlining a proposed capital raising via a placement or similar issue structure, planning to issue up to 833,333,331 new ordinary fully paid shares. The proposal also includes ...
Radiopharm Theranostics Plans Major Share and Option Issuance for Capital Raise
Jul 24, 2026
Radiopharm Theranostics plans a substantial capital raise through a securities purchase plan, proposing to issue up to 400 million fully paid ordinary shares and 400 million options expiring July 31, 2029, with a record date of July 23, 2026 and a...
Radiopharm Theranostics raises up to A$18.5m to fund Phase 3 push and pipeline
Jul 24, 2026
Radiopharm Theranostics has secured firm commitments for an institutional capital raising of about A$12.5 million, comprising a two-tranche Australian placement and a concurrent U.S. direct registered offering of American Depositary Shares. The Au...
Radiopharm Theranostics Seeks ASX Suspension Ahead of Capital Raising
Jul 23, 2026
Radiopharm Theranostics Limited has requested the suspension of trading in its securities on the ASX under Listing Rule 17.2, following an earlier trading halt and pending the release of an announcement. The company indicated the halt and voluntar...
Radiopharm Theranostics Seeks Trading Halt Ahead of Capital Raising
Jul 21, 2026
Radiopharm Theranostics Limited has requested an immediate trading halt in its shares on the ASX, pending the release of an announcement regarding a material capital raising. The halt, approved by ASX Compliance, will remain in place until either ...
Radiopharm posts durable response, clean safety profile in Phase 1 RAD204 trial
Jul 21, 2026
Radiopharm Theranostics reported updated data from its ongoing first-in-human Phase 1 trial of RAD204, a PD-L1–targeted lutetium-177 nanobody radiotherapeutic in patients with advanced solid tumors that have progressed after immunotherapy. T...
Radiopharm posts strong Phase 2b data for brain metastases imaging agent RAD101
Jul 21, 2026
Radiopharm Theranostics has reported positive Phase 2b trial data for its imaging agent RAD101, used to evaluate suspected recurrent brain metastases after stereotactic radiosurgery. In 30 evaluable patients, RAD101 PET imaging showed 93% concorda...
Radiopharm Secures A$5.9m R&D Tax Refund to Fuel Cancer Radiopharmaceutical Pipeline
Jul 3, 2026
Radiopharm Theranostics has received an A$5.9 million research and development tax refund from the Australian Government for the 2025 financial year, including interest, under the national RD tax incentive program. The refundable tax offset, which...
Radiopharm Theranostics Issues New Employee Incentive Options
Jun 30, 2026
Radiopharm Theranostics Limited operates in the medical and biotechnology sector, focusing on radiopharmaceuticals and theranostic solutions that combine diagnostic imaging with targeted therapy. The company is listed on the ASX under the ticker R...
Radiopharm Theranostics Cuts Future Dilution as Unmet Option Conditions Trigger Lapse
Jun 30, 2026
Radiopharm Theranostics Limited has reported the cessation of multiple series of options on its ordinary shares, listed under ASX code RAD, after the underlying conditions for exercise were not met. The lapsed instruments include more than 37 mill...
Radiopharm Theranostics Options Lapse, Tightening Capital Structure
Jun 3, 2026
Radiopharm Theranostics Limited reported the expiry of 505,598 options, classified as RADAN options with various expiry dates and exercise prices, which lapsed without being exercised by 31 May 2026. The cessation of these options slightly reduces...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.